‘Frame policy for docus for disability certs'
A division bench of Chief Justice T S Sivagnanam and Justice Chaitali Chatterjee Das issued the directive after counsel for the petitioners, Kaushik Gupta, highlighted the disparate documents sought from people applying for Unique Disability Identity Cards under UDID.
"R G Kar insists on a permanent residence certificate from the councillor though NRS does not," Gupta said.
The division bench held
Aadhaar
and voter ID cards, passport, passbook and parents' driving licence could be relied on as residence proof. The CJ directed the authorities to frame a uniform policy for all hospitals in the state.
You Can Also Check:
Kolkata AQI
|
Weather in Kolkata
|
Bank Holidays in Kolkata
|
Public Holidays in Kolkata
The counsel said at NRS Hospital, persons with disabilities had to go to the basement for scrutiny.
"There is no ramp to the basement, forcing them to use the stairs," Gupta said. The CJ said ramps were mandatory at hospitals, and the state PWD should act immediately.
HC welcomed the state move to give patients with muscular dystrophy, and rare diseases, with free supportive drugs for two months. State counsel Tapan Kumar Mukherjee said the state was considering hiking monthly stipend of such patients from Rs 1,000 to Rs 5,000.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
25 minutes ago
- Time of India
Begging for answers: DNA seeks missing link in Ludhiana.
Ludhiana: In a major step to combat child trafficking and forced begging, the health department collected DNA samples from six rescued children at the civil hospital on Wednesday in the presence of the district child protection officer (DCPO) and police personnel as part of Project Jeevanjot 2.0. The move comes two days after the district administration faced a setback when hospital staff refused to take DNA samples, citing a lack of official guidelines. In response, deputy commissioner Sakshi Sawhney constituted a high-level committee comprising the DCPO, civil surgeon, and representatives from the police commissioner to oversee the testing process. DCPO Rashmi Saini said the six children were accompanied by adults who claimed to be their parents but had failed to produce any valid documents such as Aadhaar cards or birth certificates. Consent for the DNA testing was reportedly taken from the adults present. However, the process raised ethical questions within the health department, with one official noting the unusual nature of taking consent from individuals who may be implicated in trafficking if the DNA results prove otherwise. The Child Welfare Committee (CWC) chairman, Gurjit Singh Romana, confirmed that the testing had been carried out under the committee's direction. He said legal action would be initiated if biological links between the children and the adults could not be confirmed. Of the 18 children rescued from the streets of Ludhiana, only one child's biological relationship was verified through documentation, while 11 remain unclaimed, and efforts to establish their identities continue. Any adult found to be claiming parental ties falsely may face legal charges under a range of laws, including the Bharatiya Nyaya Sanhita (BNS), Juvenile Justice Act, Child Labour Act, and Bonded Labour Abolition Act. The photos and profiles of unidentified children will also be uploaded to the Track the Child Portal to help locate their real families. Each child will have an individual case file compiled by the DCPO, detailing everything from DNA test records and social investigation reports to any benefits provided and information about the accompanying adult. The administration said the children have been relocated to safe temporary shelters while verification is underway. MSID:: 122863372 413 |
Time of India
2 hours ago
- Time of India
Body of Kodagu man being brought back from Guyana
Madikeri: Mortal remains of a resident of Kodagu, who died in Guyana, will be brought back to India, the Non-Resident Indian Forum said on Wednesday. The state govt will extend financial assistance to bring back the body of PB Girish Babu Pale, who is a native of Madenadu village in Madikeri taluk, it stated. Girish was working as a staff nurse in the Sheriff General Hospital in Guyana, South America, for about two years. On July 3, he was admitted to the hospital where he was working due to illness and was undergoing treatment. However, he died of a heart attack on July 14. Following the incident, the family was in constant touch with the hospital and the Indian Embassy to bring the mortal remains to India. The embassy informed that the family of the deceased would have to pay about Rs 12 lakhs to bring the mortal remains to India. Janaki, wife of Girish, appealed to the Non-Resident Indian Forum for assistance from the govt, stating that the family was financially backward. Accordingly, the forum requested chief minister Siddaramaiah to consider the request. Janaki also met the CM and sought his intervention. In response, the state govt sanctioned Rs 3.6 lakh while the remaining amount is being borne by the Sheriff General Hospital where Girish worked, the Forum stated on Wednesday. In addition, the alumni of Basavanahalli Morarji Desai Residential School, where Girish studied, approached Virajpet MLA AS Ponnanna and requested him to provide financial assistance. The Indian Embassy in Guyana and the resident commissioner in New Delhi are coordinating the bringing of the body to India.
Economic Times
3 hours ago
- Economic Times
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
Dr. Reddy's Laboratories is closely monitoring a potential US tariff on the pharma sector, viewing it as both a risk and opportunity. The company plans a significant expansion with the generic version of semaglutide across 87 countries by 2026, alongside developing 26 GLP-1 products over the next decade. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET.'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.'The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver.'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query.'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade.'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio company's India and emerging markets business grew 11% and 17% company's EBITDA margin for the first quarter stood at 26.7%.
